Farmas USA

Se viene una ola de ODD's el próximo trimestre

FDA unveils plan to eliminate orphan designation backlog

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm565148.htm

Nasdaq biotecnología y otros, ¿ cambio sectorial en flujos de capitales?

https://inbestia.com/analisis/nasdaq-biotecnologia-y-otros-cambio-sectorial-de-flujos-de-capitales

A ver si tiene razón! 

Inversiones variopintas off-topic (especialmente interesante el ETF "MILN" sobre los millennials...). Nah, para pasar el rato. El de marihuana tampoco es tan raro en este foro.

Drogas, religión, obesos, videojuegos... Las inversiones más raras de Wall Street

http://www.lavanguardia.com/economia/20170629/423745770871/fondos-marihuana-gordos-wall-street.html

CARA

hoy está más barata, malos datos de su opioide para paliar el OA

-30%

https://www.fool.com/investing/2017/06/30/why-cara-therapeutics-stock-is-crashing.aspx

The Stem Cell Revolution

y CRISPR

Enhanced Safety Profile: CRISPR-edited stem cell therapies should offer a safer class of therapeutics than any other technology. While CRISPR technology is often criticized for off-target effects, they occur less frequently in iPSCs than in other cells lines. Moreover, with stem cell therapy alone, patients have to undergo chemotherapy, suffering dangerous side effects. CRISPR-edited stem cell therapy eliminates the need for chemotherapy, while mitigating off-target effects.

Higher Efficiency and Lower Costs: iPSC cells spontaneously transform into more specialized cells, often making labwork quite difficult. With a shorter editing turnaround time, CRISPR lowers the probability that iPSCs differentiate into mature cells before the proper edits have been made, ensuring that the corrected genome is passed on to specialized cells. Typically, experiments require control tests, but replicating stem cell generated environments can be difficult. Alleviating that problem, CRISPR normalizes the genetic variability that exists across different iPSC cell lines. Additionally, CRISPRi, an application of CRISPR technology that silences genes instead of editing them, can reach efficiency levels of up to 95% in stem cells.

Editas Medicine (EDIT) signed a stem cell pact with GlaxoSmithKline (GSK) and Biogen (BIIB) for next-gen stem-cell therapies; CRISPR Therapeutics (CRSP) CRSP),+Casebia+Therapeutics+Sign+Commercial+License+Agreement+to+MaxCyte/12664463.html" rel="nofollow">licensed a CRISPR delivery mechanism for blood stem cells and has formed a CRISPR joint venture with Bayer (BAYZF); and Intellia Therapeutics (NTLA) has partnered with biotech giant Novartis NVS to focus on stem-cell based therapies.

https://seekingalpha.com/article/4084951-stem-cell-revolution

wow! primer cierre sobre los 4$ desde hace 3 años 8 meses y 11 dias

La verdad, no me esperaba esta sesion tras la shooting star de ayer.

Menudo velon mensual

IBB pullback a la zona de 303$ me parece razonable .

Mas no quisiera, la verdad.

Editas Medicine: My Pick Among Gene Editing Stocks

https://seekingalpha.com/instablog/498952-bret-jensen/5006478-editas-medicine-pick-among-gene-editing-stocks

EDIT